P14-11. Educating community medical providers about HIV vaccine induced seropositivity by Mark, KE et al.
BioMed  Central
Page 1 of 1
(page number not for citation purposes)
Retrovirology
Open Access Poster presentation
P14-11. Educating community medical providers about HIV vaccine 
induced seropositivity
KE Mark*, J Maenza, D Garcia, K Louis, SB Alexander, E Moore, GB Broder, 
S Wakefield and M McElrath
Address: Dept. of Medicine, Div. of Infectious Diseases, University of Washington and Fred Hutchinson Cancer Research Center, Seattle, WA, USA
* Corresponding author    
Background
Experimental HIV vaccines can elicit antibodies to HIV
proteins expressed by the vaccine, leading to a positive
HIV serologic test result without infection. Vaccine
induced seropositivity (VISP) can cause social harms for
trial participants and potentially threatens study validity
by unblinding participants and staff. Trial participants are
educated to avoid HIV testing outside the trial site until
trial completion or disappearance of VISP, whichever
occurs later. In 2006, the U.S. Centers for Disease Control
and Prevention released guidelines recommending that
HIV testing be performed as part of routine medical care
without specific written consent, raising concern that trial
participant education alone might be insufficient to avoid
inadvertent HIV testing of trial participants in the commu-
nity.
Methods
The Seattle HIV Vaccine Trials Unit (HVTU), in collabora-
tion with the HIV Vaccine Trials Network, conducted a
pilot project designed to educate medical and HIV test
providers in the Seattle area about VISP. We gathered local
data about vaccine study participation, sought input from
local HIV care providers and test counselors, public health
officials, and community based organizations, and devel-
oped a VISP educational program.
Results
Since 1990, >1144 persons in the Seattle area have
enrolled in HIV vaccine trials, of whom 900 (79%)
received active vaccine. Of 786 vaccine recipients complet-
ing trials between 1990–2008, 253 (32%) developed
VISP, lasting months to >10 years after vaccine receipt.
Highlights from community input included the impor-
tance of making sure that VISP education is not miscon-
strued as anti-HIV testing, continued participant
education, and desire for brief written materials for clini-
cians. From June 1, 2008–May 8, 2009, 43 VISP educa-
tional presentations were conducted, written materials
developed, and VISP education slides adapted into
required Washington state training courses reaching >400
HIV service providers.
Conclusion
The Seattle HVTU was able to successfully incorporate
VISP education into community education regarding HIV
vaccine research.
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